Klin Farmakol Farm. 2004;18(4):207-211

Interakce antipsychotik

Josef Herink
Univerzita Karlova, Farmaceutická fakulta v Hradci Králové a Ústav experimentální biofarmacie, společné pracoviště PRO.MED., a. s., Praha a AV ČR v Hradci Králové

Keywords: interactions, antipsychotic drugs, adverse effects.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Herink J. Interakce antipsychotik. Klin Farmakol Farm. 2004;18(4):207-211.

Přehled interakcí antipsychotik (neuroleptik) je podán nejprve na základě jejich klasického třídění na farmakokinetické a farmakodynamické interakce. V další části je věnována pozornost interakcím na základě vybraných nežádoucích účinků.

ANTIPSYCHOTICS INTERACTIONS

An overview of the most frequent interactions of antipsychotic drugs (neuroleptics) in relation to their pharmacokinetic and pharmacodynamic classification. In addition, interactions are discussed in relation to some characteristic adverse effects of neuroleptics.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Leucht S, Wahlbeck K, Haman J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2001; 361: 1581-1589. Go to original source... Go to PubMed...
    2. Carlsson A. Neurocircuitries and neurotransmitter interactions in schizophrenia. Intern Clin Psychopharmacol 1995; 10: 21-28. Go to original source...
    3. Kopeček M. Klinické a teoretické aspekty podávání antipsychotik (neuroleptik). Remedia 2002; 12: 447-465.
    4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564. Go to original source... Go to PubMed...
    5. Gerlach J, Peacock L. New Antipsychotics: the present status. Intern Clin Psychopharmacol 1995; 10 (suppl 3): 39-48. Go to original source...
    6. Mortimer AM. Newer and older antipsychotics. A comparative review of appropriate use. CNS Drugs 1994; 2: 381-396. Go to original source...
    7. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13: 57-67. Go to original source... Go to PubMed...
    8. Tatro DS, ed. Drug interaction facts. 1st ed. St Louis: A Wolters Kluwer Company, 2001: 49-1215.
    9. Květina J, Fendrich Z. Farmakologické interakce. 1st ed. Praha: Avicenum, 1978: 11-108.
    10. Květina J, Grundmann M. Farmakologické interakce. Klin Farmakol Farm 2003; 1: 17-21.
    11. Forrest FM, Forrest IS, Serra MT. Modification of chlorpromazine metabolism by some drugs frequently administered to psychiatric patients. Biol Psychiat 1970; 2: 35. Go to original source...
    12. Kořínková V. Interakcie psychofarmák. In: Magulová L, Božeková L, Kriška M, eds. Interakcie liečiv v klinickej praxi. 1st ed. Bratislava: Slovak Academic Press, 2003: 253-272.
    13. Karalliedde L, Henry J, eds. Handbook of drug interactions. 1st ed. London: Arnold, 1998: 643-718.
    14. Sunderland T, Cohen BM. Blood to brain distribution of neuroleptics. Psychiat Res 1987; 20: 299-305. Go to original source... Go to PubMed...
    15. Baranová J, Anzenbacher P, Kousalová L. Liekové interakcie na úrovni cytochrómov P450. II. Interakcie na úrovni CYP2D6. Klin Farmakol Farm 2004; 18: 102-107.
    16. Hadašová E. Genetický polymorfismus metabolismu psychotropních látek a jeho klinické důsledky. ČS Psychiat 1995; 91: 352-360. Go to original source...
    17. Kousalová L, Baranová J, Anzenbacher P. Lékové interakce na úrovni cytochromů P450. I. Interakce na úrovni CYP3A4. Klin Farmakol Farm 2003; 17: 151-157.
    18. Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 1995; 15: 139-141. Go to original source... Go to PubMed...
    19. Haidukewych D, Rodin EA. Effect of phenothiazines on serum antiepileptic drug concentrations in psychiatric patients with seizure disorders. Ther Drug Monitoring 1985; 7" 401. Go to original source... Go to PubMed...
    20. Tate JL. Extrapyramidal symptoms in patient taking haloperidol and fluoxetine. Am J. Psychiat 1989; 146: 399-400. Go to original source... Go to PubMed...
    21. Cobb CD, Anderson CB, Seidel DR. Possible interaction between clozapine and lorazepam. Am J Psychiat 1991; 148: 1606-1607. Go to original source... Go to PubMed...
    22. Češková E. Úskalí dlouhodobé léčby atypickými neuroleptiky. ČS Psychiat 2000; 322-327.
    23. Švestka J. Psychofarmaka v klinické praxi. 1st ed. Praha: Grada Publishing, 1995: 179-181.
    24. Stockley EC, ed. Drug interactions - a source book for adverse interactions: their mechanisms, clinical importance and management. 3rd ed. Oxford: Blackwell Scientific Publications, 1994: 538-576.
    25. Potter JM, Reid DB, Straw RJ. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs, Brit Med J 1989; 299: 150-153. Go to original source... Go to PubMed...
    26. Švestka J, Doležal T. Clozapinum. Remedia 2000; 10: 376-392. Go to original source...
    27. Harvey NS, Merriman S. Review of clinically important drug interactions with lithium. Drug Safety 1994; 10: 455-463. Go to original source... Go to PubMed...
    28. Spring GK: Neurotoxicity with combined use of lithium and thioridazine. J Clin Psychiat 1979; 40: 135.
    29. Tune I, Carr S, Hoag E. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiat 1992; 149: 1393-1394. Go to original source... Go to PubMed...
    30. Lávička V. Antipsychotika z pohledu internisty. Psychiatrie pro praxi 2000; 1: 96-98.
    31. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assesing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002; 63 (suppl. 9): 25-29.
    32. Sovová E, Doupal V, Lukl J. Léky a lékové interakce vedoucí k, ,long QT" syndromu - myslíme na ně? Klin Farmakol Farm 2000; 15: 21-23.
    33. Welch R. Antipsychotic agents and QT changes. J Psych Neurosci 2000; 25: 154-160.
    34. Hell K, Wernze H. Drug-induced changes in prolactin secretion. Clinical implications. Med Toxicology 1988; 3: 463-498. Go to original source... Go to PubMed...
    35. Marek J. Prolaktin a psychofarmakologie. Psychiatrie 2004; 8 (suppl 2): 8-15.
    36. Pidrman V. Amisulprid - mýty a fakta. Psychiatrie pro praxi 2004; 5: 276-280.
    37. Hummer M, Huber J. Hyperprolactinemia and antipsychotic therapy in schizofrenia. Curr Med Res Opinion 2004; 20: 189-197. Go to original source... Go to PubMed...
    38. Gratz SS, Simpson GM. Neuroleptic malignant syndrome. CNS Drugs 1994; 2: 429-439. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.